secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-203913
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Damora Therapeutics CFO Lori Firmani to depart May 1; Brian Burkavage appointed principal financial officer
--------------------------------------------------------------------------------

- Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
- Firmani receives lump-sum salary continuation, prorated bonus, $6K HSA, and full equity acceleration.
- Brian Burkavage, current SVP Finance, appointed principal financial and accounting officer effective May 1.
- Burkavage previously SVP Finance and CAO at IO Biotech; CPA with 11 years at Ernst & Young.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526203913/0001193125-26-203913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526203913/dmra-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-203913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer